Santhera Pharmaceuticals Holding (S3F0) Stock Overview
A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
S3F0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Santhera Pharmaceuticals Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 16.82 |
| 52 Week High | CHF 20.20 |
| 52 Week Low | CHF 12.96 |
| Beta | -0.28 |
| 1 Month Change | 2.81% |
| 3 Month Change | -5.61% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| S3F0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.8% | -1.2% | -0.005% |
| 1Y | n/a | 3.8% | 3.3% |
Return vs Industry: Insufficient data to determine how S3F0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how S3F0 performed against the German Market.
Price Volatility
| S3F0 volatility | |
|---|---|
| S3F0 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: S3F0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: S3F0's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 94 | Orlando Oliveira | www.santhera.com |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Santhera Pharmaceuticals Holding AG Fundamentals Summary
| S3F0 fundamental statistics | |
|---|---|
| Market cap | €267.49m |
| Earnings (TTM) | -€52.34m |
| Revenue (TTM) | €82.05m |
Is S3F0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S3F0 income statement (TTM) | |
|---|---|
| Revenue | CHF 77.19m |
| Cost of Revenue | CHF 62.01m |
| Gross Profit | CHF 15.17m |
| Other Expenses | CHF 64.41m |
| Earnings | -CHF 49.24m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 19.66% |
| Net Profit Margin | -63.79% |
| Debt/Equity Ratio | -397.7% |
How did S3F0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/18 01:56 |
| End of Day Share Price | 2026/08/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Santhera Pharmaceuticals Holding AG is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Parkes | Piper Sandler Companies |
| null null | RBC Capital Markets |
| Christian Glennie | Stifel, Equities Research |